Semi-quantification image methods for assessing severity of scleroderma-associated interstitial lung disease according to computed tomography data

The aim of this study was to compare three semi-quantification scales for prospective assessment of scleroderma-associated interstitial lung disease (SS-ILD) severity. Methods. From 110 prospectively followed patients with SS-ILD, we selected 12 patients (mean age, 42 ± 13 years, 11 females) with obvious improvement (n = 6) or worsening (n = 6) of lung lesions on high resolution computed tomography (HRCT) during a year. The patients had diffuse (n = 7) or limited (n = 7) SS with mean length of the disease of 8.5 ± 6.7 years (range, 1 to 23 years). HRCT was done at baseline (inclusion in the study) and in a year. CT scans were quantitatively assessed by four radiologists including one experienced radiologist. A blinded analysis of HRCT scans was done using three scales: J.H.Warrick et al. (1991), A.U.Wells et al. (1997), and E.A.Kazerooni et al. (1997). The intraclass correlation coefficient (ICC) was calculated to evaluate the assessment reliability. T-test for independent samples was used to evaluate reproducibility of the assessments. Agreement between independent experts' opinions was evaluated using Kendall's rank correlation coefficient. Results. The measurements were significantly divergent between the radiologists, both for the baseline and the follow-up HRCT scans. ICCs for investigated radiological parameters were 0.56 to 0.76. The highest ICC (0.76) was obtained for A.U.Wells' scale. All scales used to assess HRCT scans had lower interoperator reproducibility. Conclusion. Combined use of currently available semi-quantification methods for follow-up assessment of HRCT in SS-ILD patients allowed thorough qualitative evaluation of lung lesions, but the reliability of the radiological parameters in detecting 1-year fibrosis progression in SS patients was low. The risk of significant interoperator bias limited the use of the radiological parameters in clinical trials of SS-ILD patients.

1. American Thoracic Society / European Resperatory Society International Multidisciplinary Consensus Classification of the Idiopatic Interstitial Pneumanias. Am. J. Respir. Crit. Care Med. 2002; 165 (2): 277–304. DOI: 10.1164/ajrccm.165.2.ats01.

2. Guseva N.G. Systemic scleroderma and pseudoscleroderma syndromes. Moscow: Meditsina; 1993: 75–82 (in Russian).

3. Goldin J.G., Lynch D.A., Strollo D.C. et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008; 134 (2): 358–367. DOI: 10.1378/chest.07-2444.

4. Afeltra A., Zennaro D., Garzia P. et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scan. J. Rheumatol. 2006; 35 (5): 388–394. DOI: 10.1080/03009740600844381.

5. Teplova L.V., Anan'eva L.P., Lesnyak V.N., et al. Systemic scleroderma with interstitial lung disease: comparative characteristics of patients with and without lung injury. Nauchno-prakticheskaya revmatologiya. 2010; 3: 41–47 (in Russian).

6. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis. 2007; 66 (7): 940–944. DOI: 10.1136/ard.2006.066068.

7. Bouros D., Wells A.U., Nicholson A.G. et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am. J. Respir. Crit. Care Med. 2002; 165 (12): 1581–1586. DOI: 10.1164/rccm.2106012.

8. Goldin J.G., Lynch D.A., Strollo D.C. et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008; 134 (2): 358–367. DOI: 10.1378/chest.07-2444.

9. Launay D., Remy-Jardin M., Michon-Pasturel U. et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J. Rheumatol. 2006; 33: 1789–1801.

10. Goh N.S., Desai S.R., Veeraraghavan S. et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med. 2008; 177 (11): 1248–1254. DOI: 10.1164/rccm.200706-877OC.

11. Goldin J., Elashoff R., Kim H.J. et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009; 136 (5):1333–1340. DOI: 10.1378/chest.09-0108.

12. Tochimoto A., Kawazuchi Y., Hara M. et al. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral ptednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod. Rheumatol. 2011; 21 (3): 296–301. DOI: 10.1007/s10165-010-0403-6.

13. Moore O.A., Goh N., Corte T. et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford). 2013; 52 (1): 155–160. DOI: 10.1093/rheumatology/kes289.

14. Warrick J.H., Bhalla M., Schabel S.I., Silver R.M. High resolution computed tomography in early scleroderma lung disease. J. Rheum. 1991; 18 (10): 1520–1528.

15. Wells A.U., Hansell D.M., Rubens M.B. et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum. 1997; 40 (7): 1229–1236.

16. Kazerooni E.A., Martinez F.J., Flint A. et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. Am. J. Roentgenol. 1997; 169 (4): 977–983. DOI: 10.2214/ajr.169.4.9308447.

17. Van den Hoogen F., Khanna D., Fransen J. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology / European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65 (11): 2737–2747. DOI: 10.1002/art.38098.

18. Smidt N., Rutjes A., van der Windt D.et al. Reproducibility of the STRAD checklist: an instrument to assess the quality of reporting of diagnostic accuracy studies. BMC Med. Res. Methodol. 2006; 6: 12. DOI: 10.1186/1471-2288-6-12.

19. Wells A.U., Hansell D.M., Corrin B. et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax. 1992; 47: 738–742.

20. Desai S.R., Veeraraghavan S., Hansell D.M. at al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004; 232 (2): 560–567. DOI: 10.1148/radiol.2322031223.

21. Camiciotolli G., Orlandi I., Bartolucci M. et al. Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. Chest. 2007; 131 (3): 672–681. DOI: 10.1378/chest.06-1401.

22. Assayag D., Kaduri S., Hudson M. et al. High resolution computed tomography scoring systems for evaluating interstitial lung disease in systemic sclerosis patients. Rheumatology. 2012; S1: 003. DOI: 10.4172/2161-1149.S1-003.